Company Overview - Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, particularly epilepsy [1][13] - The company utilizes proprietary small molecule and antisense oligonucleotide (ASO) platforms to address neurological disorders characterized by neuronal excitation-inhibition imbalance [13] Upcoming Event Participation - Praxis will participate in the International Epilepsy Congress (IEC) from August 30 to September 3, 2025, in Lisbon, Portugal, showcasing its advancements in epilepsy treatment [1][2] - The company plans to present topline results from the RADIANT study in focal onset seizures (FOS) and share updates on its precision epilepsy pipeline through twelve presentations [2][4] Research and Development Highlights - Vormatrigine, a small molecule targeting sodium channels, is being developed for adult focal onset seizures and generalized epilepsy, showing robust seizure reduction in clinical studies [4][8] - Relutrigine, a first-in-class small molecule for developmental and epileptic encephalopathies (DEEs), has demonstrated significant seizure control in preclinical models and received multiple designations from regulatory agencies [11][12] - Elsunersen, an ASO targeting SCN2A gene expression, has shown promise in reducing seizures and improving outcomes in SCN2A-DEE models, with ongoing studies under collaboration with Ionis Pharmaceuticals [12][13] Presentation Schedule - Praxis will conduct various presentations during the IEC, including platform and poster presentations, detailing the predictive validity of preclinical seizure models and updates from ongoing studies [3][6][10]